| WB | 1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Complement C3, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1, Complement C3 beta chain, C3-beta-c, C3bc, Complement C3 alpha chain, C3a anaphylatoxin, Acylation stimulating protein, ASP, C3adesArg, Complement C3b alpha' chain, Complement C3c alpha' chain fragment 1, Complement C3dg fragment, Complement C3g fragment, Complement C3d fragment, Complement C3f fragment, Complement C3c alpha' chain fragment 2, C3, CPAMD1 |
| Entrez GeneID | 718 |
| WB Predicted band size | 187.1kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This C3 antibody is generated from mice immunized with a KLH conjugated synthetic peptide between 1353-1382 amino acids from the C-terminal region of human C3. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于C3抗体的3篇示例文献(内容为模拟示例，仅供参考)：
---
1. **文献名称**：*Targeting Complement C3 with a Novel Antibody Inhibits Chronic Inflammation in Autoimmune Disease Models*
**作者**：Smith, J. et al.
**摘要**：研究开发了一种靶向补体C3的新型单克隆抗体，通过阻断C3的裂解抑制补体旁路和经典途径的激活。在类风湿性关节炎和狼疮小鼠模型中，该抗体显著减少炎症细胞浸润和组织损伤，提示其作为自身免疫疾病治疗的潜力。
2. **文献名称**：*Structural Insights into C3 Antibody Binding Epitopes via Cryo-EM Analysis*
**作者**：Chen, L. & Wang, H.
**摘要**：通过冷冻电镜技术解析了C3蛋白与其特异性抗体的复合物结构，揭示了抗体与C3的α链关键表位结合机制。该研究为设计高亲和力C3抑制剂提供了分子基础。
3. **文献名称**：*Anti-C3 Antibody Therapy Attenuates Ischemia-Reperfusion Injury in a Porcine Kidney Transplant Model*
**作者**：Rodriguez, S. et al.
**摘要**：在猪肾脏移植模型中，使用人源化C3抗体预处理移植物，有效抑制补体介导的缺血-再灌注损伤，改善肾功能并延长移植物存活时间，证明其在器官移植中的临床应用价值。
---
**注**：以上文献信息为示例性内容，实际引用需根据真实发表的文献进行核实。建议通过PubMed、Web of Science等数据库搜索关键词(如“C3 antibody”、“complement C3 inhibitor”)获取最新研究。
C3 antibodies are essential tools in studying the complement system, a critical component of innate immunity. C3. a central protein in complement activation, plays a pivotal role in all three pathways (classical, lectin, and alternative). Its cleavage into C3a and C3b drives key immune processes, including opsonization, inflammation, and membrane attack complex formation. C3 antibodies, both monoclonal and polyclonal, are widely used to detect C3 activation fragments in research and diagnostics, aiding in understanding diseases linked to complement dysregulation, such as autoimmune disorders, atypical hemolytic uremic syndrome, and age-related macular degeneration.
Therapeutic C3-targeting antibodies (e.g., compstatin derivatives) are emerging to modulate excessive complement activation in conditions like paroxysmal nocturnal hemoglobinuria. These inhibitors block C3 convertase activity, preventing downstream inflammatory damage. Commercially available C3 antibodies also serve as standards in assays to quantify complement activity or diagnose deficiencies.
Cross-reactivity across species (human, mouse, rat) enhances their utility in preclinical models. However, challenges remain in balancing therapeutic efficacy with infection risks due to systemic complement suppression. Ongoing research focuses on optimizing C3 antibody specificity and delivery to refine their clinical application in complement-mediated pathologies.
×
